Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Targets |
HT-1080 ferroptotic cell death (EC50 = 6 nM)
|
---|---|
ln Vitro |
SRS11-92 fully protects oligodendrocytes (OLs) from cystine deprivation when tested at 100 nM. When frataxin is knocked down, SRS11-92 prevents the death of primary human fibroblasts[2].
|
ln Vivo |
In contrast to caspase-3 inhibitors, SRS11-92 is effective at protecting human and mouse cellular models of Friedreich ataxia (FRDA) treated with ferric ammonium citrate (FAC) and an inhibitor of glutathione synthesis (BSO)[2].
|
References |
Molecular Formula |
C22H28N2O2
|
---|---|
Molecular Weight |
352.5
|
Exact Mass |
352.215078140
|
CAS # |
1467047-25-1
|
Related CAS # |
1467047-25-1
|
Appearance |
Solid
|
SMILES |
CCOC(=O)C1=CC(=C(C=C1)NC2CCCCC2)NCC3=CC=CC=C3
|
InChi Key |
VHQAJFNLPQULSV-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C22H28N2O2/c1-2-26-22(25)18-13-14-20(24-19-11-7-4-8-12-19)21(15-18)23-16-17-9-5-3-6-10-17/h3,5-6,9-10,13-15,19,23-24H,2,4,7-8,11-12,16H2,1H3
|
Chemical Name |
ethyl 3-(benzylamino)-4-(cyclohexylamino)benzoate
|
Synonyms |
SRS1192; SRS11 92; SRS11-92
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: 70~250 mg/mL (198.6~709.3 mM)
Ethanol: 70 mg/mL (~198.6 mM) |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: 2.08 mg/mL (5.90 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.90 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.8369 mL | 14.1844 mL | 28.3688 mL | |
5 mM | 0.5674 mL | 2.8369 mL | 5.6738 mL | |
10 mM | 0.2837 mL | 1.4184 mL | 2.8369 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
The ferroptosis inhibitor SRS11-92 rescues primary human fibroblasts from death induced by frataxin knockdown. J Pharmacol Exp Ther . 2019 Apr;369(1):47-54. td> |